BiotechTube
Eyenuk

Eyenuk

Los Angeles, United States· Est.
eyenuk.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $34M

Overview

Eyenuk is a pioneering, commercial-stage AI diagnostics company focused on preventing vision loss through autonomous eye screening. Its core technology, the EyeArt system, is the world's most extensively validated AI for diabetic retinopathy detection and holds the distinction of being the first with multiple camera clearances from the FDA and the first EU MDR certification for autonomous AI detection of DR, AMD, and glaucoma. The company is transitioning its leadership and has secured a landmark national health system deployment, positioning it for significant scale in addressing the massive global backlog of undiagnosed eye disease. Eyenuk operates as a private company, generating revenue through its diagnostic platform and services.

OphthalmologyDiabetes

Technology Platform

Deep learning and image analysis platform for autonomous detection of retinal diseases (diabetic retinopathy, age-related macular degeneration, glaucoma) from fundus photographs. Includes real-time image quality feedback and generates reports in under 60 seconds.

Funding History

5
Total raised:$34M
Series C$16M
Grant$2M
Series B$10M
Series A$5M

Opportunities

The massive and growing global diabetic population creates a critical need for scalable screening solutions, which Eyenuk's autonomous AI directly addresses.
Expansion into AMD and glaucoma screening via its EU MDR certification opens additional large markets, particularly in aging populations.
The long-term opportunity in AI Predictive Biomarkers could revolutionize preventive care by using retinal images to predict systemic disease risk.

Risk Factors

Commercial execution risk is high, as scaling a national health system deployment and global operations is complex.
The evolving regulatory landscape for AI-based medical software and the ongoing challenge of securing consistent reimbursement from payors pose significant hurdles.
Competition in the AI ophthalmology space is intensifying from both startups and large medtech incumbents.

Competitive Landscape

The competitive landscape for AI-based retinal diagnostics includes specialized startups (e.g., IDx Technologies, now part of Digital Diagnostics; RetinAI; AEYE Health) and large medical technology companies integrating AI into their imaging systems (e.g., Zeiss, Topcon, Nikon/Optos). Eyenuk's key competitive advantages are its first EU MDR certification for multi-disease detection, FDA clearance for use with multiple cameras, and extensive real-world validation data.

More companies in AI / Machine Learning →More companies in United States →